Summary
Alnylam Pharmaceuticals, Inc. (ALNY) has filed a Form 8-K on January 16, 2013, to announce a significant underwritten public offering of its common stock. The company is selling 8,000,000 shares at a public offering price of $20.13 per share, with an option for underwriters to purchase an additional 1,200,000 shares. This offering is expected to generate approximately $151.1 million in net proceeds for Alnylam, before considering the exercise of the overallotment option.
Key Highlights
- 1Alnylam Pharmaceuticals entered into an underwriting agreement on January 15, 2013, for a public offering of common stock.
- 2The offering consists of 8,000,000 shares of common stock.
- 3The public offering price is set at $20.13 per share.
- 4Alnylam expects to receive net proceeds of approximately $151.1 million from the offering.
- 5The underwriters have a 30-day option to purchase up to an additional 1,200,000 shares to cover overallotments.
- 6The offering is being conducted under a shelf registration statement filed in December 2012.
- 7The closing of the offering is anticipated on January 22, 2013.
Frequently Asked Questions
This Form 8-K is filed to announce the details of a material definitive agreement, specifically an underwriting agreement for a public offering of Alnylam Pharmaceuticals' common stock.
Alnylam Pharmaceuticals expects to raise approximately $151.1 million in net proceeds from the sale of 8,000,000 shares of common stock, before accounting for any overallotment option exercised by the underwriters.
The underwriters for this offering are J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, acting as representatives of the several underwriters.
The offering price to the public is $20.13 per share.